Your Article Summary
See Latest ArticlesEGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Journal of Thoracic Oncology, 03/06/08
Fong T et al. - Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the treatment of advanced non-small cell lung cancer (NSCLC). Patients with advanced NSCLC who are life long never-smokers, have EGFR TK mutations, and those with bronchioloalveolar cell carcinoma histology seem to have promising efficacy with first-line therapy with EGFR TKIs. This review summarizes the results of clinical trials on erlotinib or gefitinib, and describes the ongoing studies with these agents in NSCLC.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Inhaled Corticosteroids Should Be Initiated Before Discharge from the Emergency Department in Patients with Persistent Asthma
Journal of Asthma, 12/15/09
Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma
European Respiratory Journal , 12/15/09
Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer
International Journal of Clinical Oncology, 12/15/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Inhalation exposure to ambient polycyclic aromatic hydrocarbons and lung cancer risk of Chinese population
Proceedings of the National Academy of Sciences of the United States of America, 12/16/09
A Small Step Towards Personalized Medicine for Non-small Cell Lung Cancer
Discovery Medicine, 12/15/09
Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients
International Journal of Clinical Oncology, 12/15/09